FindTrial
Sign In

Clinical study on intravenous drip and aerosol inhalation of polymyxin B for the treatment of pneumonia due to multidrug-resistant gram-negative bacteria

Clinical study on intravenous drip and aerosol inhalation of polymyxin B for the treatment of pneumonia due to multidrug-resistant gram-negative bacteria

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044087
Enrollment
Unknown
Registered
2021-03-09
Start date
2020-01-01
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia due to multidrug-resistant gram-negative bacteria

Interventions

Control group:Single intravenous drip of Polymyxin B
Combination group:Intravenous drip combined with aerosol inhalation of Polymyxin B

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria of pneumonia specified by Chinese Society of Respiratory Diseases; 2. Multi drug-resistant G- bacteria were detected in sputum culture, which were sensitive to polymyxin; 3. Use of polymyxin B >=3d.

Exclusion criteria

Exclusion criteria: 1. Dying dynamo; 2. Severe hepatic and renal insufficiency.

Design outcomes

Primary

MeasureTime frame
Bacterial clearance rate;Clinical efficiency rate;Recovery time of body temperature;The time of bacterial clearance;Serum procalcitonin;Incidence of nephrotoxicity;—

Countries

China

Contacts

Public ContactCunrong Chen

Fujian Medical University Union Hospital

13705056799@139.com+86 13705056799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026